Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NCK1 | P16333 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975885 | 0.85 | HRH4 (0.51) | ADORA2AHRH4KCNH2HSP90AB1LMNA | |
| SCHEMBL16222434 | 0.83 | NCK1 (0.42) | ADORA2AHRH4KCNH2HSP90AB1LMNA | |
| SCHEMBL24629140 | 0.82 | DHFR (0.51) | ADORA2AHRH4KCNH2HSP90AB1 | |
| SCHEMBL6679745 | 0.81 | HRH4 (0.58) | ADORA2AHRH4HSP90AA1 | |
| SCHEMBL15450912 | 0.81 | ALDH1A1 (0.60) | ADORA2AHRH4HSP90AA1KCNH2HSP90AB1 | |
| SCHEMBL8284883 | 0.81 | LMNA (0.47) | LMNARAD52SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27474146 | 0.81 | LMNA (0.47) | LMNARAD52SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13975087 | 0.79 | ALDH1A1 (0.37) | ADORA2AHRH4HSP90AA1HSP90AB1LMNA | |
| SCHEMBL30201967 | 0.78 | ADORA2A (0.51) | ADORA2AACHEBCHEGRIN1GRIN2A | |
| SCHEMBL13975523 | 0.78 | NPC1 (0.46) | ADORA2AKCNH2ACHEBCHEGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709989-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| EP-1511852-B1 | USE OF FLUORINE NMR FOR HIGH THROUGHPUT SCREENING | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-05-26 | — | — | EP | disclosed |
| US-7470543-B2 | Methods for identifying ligands using competitive binding 1H NMR experiments | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-12-30 | — | — | US | disclosed |
| EP-1511852-A4 | USE OF FLUORINE NMR FOR HIGH THROUGHPUT SCREENING | PHARMACIA & UPJOHN CO LLC (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1511988-A4 | METHODS FOR IDENTIFYING LIGANDS USING COMPETITIVE BINDING sp 1 /sp H NMR EXPERIMENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1511988-A1 | METHODS FOR IDENTIFYING LIGANDS USING COMPETITIVE BINDING sp 1 /sp H NMR EXPERIMENTS | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511852-A2 | USE OF FLUORINE NMR FOR HIGH THROUGHPUT SCREENING | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004051214-A2 | USE OF FLUORINE NMR FOR HIGH THROUGHPUT SCREENING | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040091937-A1 | Use of fluorine NMR for high throughput screening | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2004-05-13 | — | — | US | disclosed |
| US-20040072362-A1 | Methods for identifying ligands using competitive binding 1H NMR experiments | PHARMACIA & UPJOHN COMPANY | 2004-04-15 | — | — | US | disclosed |
| WO-2003104778-A1 | METHODS FOR IDENTIFYING LIGANDS USING COMPETITIVE BINDING 1H NMR EXPERIMENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | TLR3, TLR5, TLR4 | ADORA2A 473/4885HRH4 51/4885HSP90AA1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.